RedHill Biopharma Ltd. (RDHL) Announces Positive FDA Meeting Regarding the Regulatory Path Towards NDA Submission of RHB-101 for the Treatment of Congestive Heart Failure and Hypertension
5/29/2013 9:43:23 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TEL-AVIV, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, patent-protected, new formulations and combinations of existing drugs, reported that it recently concluded a positive Type B meeting with the U.S. Food and Drug Administration (FDA) regarding its cardio drug RHB-101, a controlled release, proprietary, once-daily formulation of carvedilol, for the treatment of congestive heart failure and hypertension.
Help employers find you! Check out all the jobs and post your resume.
comments powered by